Systematic review of methodological approaches in economic evaluations of maternal and neonatal sepsis interventions in low- and middle-income countries Authors: Daniel Regan, Nicola Mountford, Joseph Coughlan Published: 2025 ABSTRACT AbstractBackgroundMaternal and neonatal sepsis remains a leading cause of preventable morbidity and mortality in low- and middle-income countries (LMICs). While economic evaluations can support resource allocation and policy decisions, it is unclear how well existing studies capture both the costs (inputs) and outcomes associated with sepsis care. This systematic review aims to examine the methodological approaches used in economic evaluations of maternal and neonatal sepsis in LMICs, to identify common practices, strengths, and limitations, rather than to summarise specific economic outcomes.MethodsWe conducted a systematic review of economic evaluations related to maternal and neonatal sepsis in LMICs. A total of 23 peer-reviewed studies were included, representing data from over 40 countries. We assessed study design, costing methods, outcome measures, time horizons, and analytic perspectives. Key limitations and strengths were identified through narrative synthesis, and statistical tests were not applicable given the heterogeneity of the data.ResultsOnly five of the 23 studies focused exclusively on sepsis, reflecting a tendency to address it within broader maternal and neonatal care interventions. We observed wide methodological variation, including inconsistent costing approaches, outcome metrics (e.g., DALYs, QALYs, lives saved), and time horizons. Many studies lacked transparency or comparability, limiting their utility for decision-makers. However, some examples demonstrated robust design and relevance to routine care contexts. Drawing on these, we identify core components of methodological best practice and present a flexible, yet rigorous, framework to support future evaluations focused more explicitly on sepsis.ConclusionsThe current evidence base for economic evaluations of maternal and neonatal sepsis in LMICs is sparse and methodologically inconsistent. By clarifying key gaps and highlighting good practice, this review provides pragmatic guidance for future studies. Strengthening economic evaluations—particularly within routine maternal and neonatal care bundles—can support better-informed decisions by planners, funders, and policymakers, ultimately improving outcomes for mothers and newborns in resource-constrained settings.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12913-025-13799-y.Keywords: Neonatal sepsis, Systematic review, Economic evaluation, Health-care intervention, LMIC Introduction In low- and middle-income countries (LMICs), where healthcare systems are typically chronically underfunded and overstretched, Cost Effectiveness Analyses (CEAs) play a critical role. Severe resource constraints necessitate careful evaluation of interventions such as improved diagnostic tools, affordable antimicrobials, and community-based care models, ensuring that scarce funds are directed toward the most impactful solutions [1]. Without robust economic evaluations, healthcare spending in LMICs risks being inefficient, exacerbating health disparities and financial burdens on already vulnerable populations [2, 3]. CEAs provide a structured framework for evaluating the economic and health impacts of interventions, allowing for prioritisation based on value for money. These evaluations systematically compare costs and health outcomes, helping policymakers make data-driven decisions on how best to allocate limited healthcare resources [4, 5]. CEAs assess both direct costs (e.g., medical expenses, hospitalisation) and indirect costs (e.g., lost productivity, long-term disability) to determine which interventions maximise health outcomes while remaining financially viable. CEAs are essential for identifying scalable interventions that can be feasibly implemented within existing health system constraints [6]. Economic evaluations have, for instance, highlighted the value of point-of-care diagnostics and task-shifting strategies (e.g., training community health workers to provide frontline care), both of which enhance access to timely sepsis management without overburdening fragile health systems [7–10]. However, applying CEA methodologies in LMICs presents unique challenges, as healthcare infrastructure, epidemiological trends, and economic conditions vary significantly across settings [11–13]. As Leech et al. (p.759) note, “Cost-effectiveness analysis can help inform healthcare spending, but its value depends on incorporating assumptions that are valid for the applicable setting [14].” Many economic evaluations focus primarily on defining cost-effectiveness thresholds rather than adapting methodologies to better reflect real-world LMIC conditions. For instance, limited availability of cost data often forces researchers to rely on modelling techniques or region-specific data extrapolation [14]. Neonatal and maternal sepsis remains a leading cause of preventable mortality in LMICs, where related mortality rates remain unacceptably high [15]. Sepsis, a life-threatening condition caused by dysregulated immune response to infection, is responsible for a significant proportion of maternal and neonatal deaths worldwide, particularly in sub-Saharan Africa and South Asia [16]. In Uganda alone, over 32,000 neonatal deaths occur annually, with sepsis accounting for approximately 20% of these cases [17]. Maternal sepsis—resulting from infections acquired during pregnancy, childbirth, post-abortion, or the postpartum period—remains one of the most common causes of maternal mortality in LMICs [18, 19]. The economic burden of sepsis extends beyond immediate healthcare expenditures. It includes long-term disability, lost workforce productivity, and catastrophic healthcare costs that often push families into financial distress [17, 20–22]. In LMICs, where a large proportion of healthcare expenses are paid out-of-pocket, sepsis-related costs can be devastating for households [23]. Many families lack financial protection, meaning that seeking timely medical care for sepsis can result in economic hardship, further perpetuating cycles of poverty and poor health outcomes [21]. Addressing maternal and neonatal sepsis through cost-effective interventions is both a public health necessity and an economic imperative [24, 25]. Failure to invest in effective sepsis prevention and management strategies could have long-term repercussions, including slower economic growth, increased disability-adjusted life years (DALYs) lost, and higher future healthcare costs due to delayed or inadequate treatment [20]. Many existing CEAs fail to integrate equity considerations, even though sepsis disproportionately affects the most economically disadvantaged populations [26]. Sustainable Development Goal (SDG) 3.2 explicitly aims to reduce neonatal mortality to 12 per 1,000 live births and under-five mortality to 25 per 1,000 live births by 2030, therefore addressing sepsis is a critical priority [27]. However, achieving this goal is contingent on improving access to cost-effective, evidence-based interventions that can be scaled sustainably in LMIC settings. While SDGs “can still be considered the most sophisticated principles/goals-based approach available” [28], implementing them within LMIC healthcare systems presents complex challenges that remain underexplored in economic evaluations. Despite technological advancements in sepsis diagnosis and treatment, systemic inefficiencies and financial constraints in LMICs often prevent their widespread implementation [29, 30]. Many existing economic evaluations focus on high-income country contexts, leading to gaps in knowledge on how these interventions can be adapted, financed, and implemented effectively in resource-limited settings [23]. Without cost-effectiveness frameworks tailored to LMIC conditions, investments in sepsis management risk being misallocated, reducing their potential impact. Despite the high burden and clear health and economic urgency of maternal and neonatal sepsis in LMICs, there is no comprehensive synthesis of the economic evaluation methods used to assess related interventions. Existing studies are limited in number and often lack consistency in methodological approaches, assumptions, and reporting standards. While some focus on cost-effectiveness thresholds, they frequently overlook broader challenges such as data scarcity, health system heterogeneity, and local economic constraints. Moreover, equity considerations, crucial given sepsis’s disproportionate impact on vulnerable populations [31], are rarely integrated into these analyses. This systematic review addresses this gap by analysing and synthesising the current literature on economic evaluations of maternal and neonatal sepsis interventions in LMICs. Specifically, it: Categorises and quantifies methodological trends in CEAs, including cost perspectives, modelling techniques, and outcome measures; Categorises and quantifies methodological trends in CEAs, including cost perspectives, modelling techniques, and outcome measures; Identifies best practices from high-quality studies to inform a more standardised protocol for future evaluations. Identifies best practices from high-quality studies to inform a more standardised protocol for future evaluations. By strengthening the evidence base and highlighting methodological gaps, this review supports the development of more context-sensitive, equitable, and rigorous economic evaluations. In doing so, it offers valuable guidance to policymakers, healthcare managers, and researchers seeking to optimise resource allocation for sepsis interventions in LMICs. Methods We developed a systematic review search strategy to identify cost-effectiveness studies of sepsis interventions in LMICs. We analysed the resulting studies to extract methodological insights. The primary objective of this review was to systematically assess how economic evaluations of maternal and neonatal sepsis have been conducted in LMICs, including study design, costing methods, outcome measures, time horizons, and analytic perspectives. We aimed to identify methodological strengths, limitations, and areas for improvement to inform future research in this field. We used key terms related to neonatal and maternal health, sepsis, economic evaluation, and low and middle-income countries. The search string used in this study was as follows: (Neonatal or maternal) AND (sepsis OR septicemia1 OR “septic shock”) AND (cost-effectiveness OR “economic evaluation”) AND (“low and middle income countries” OR LMICs OR “developing countries” OR “emerging economies”) NOT (“high income countries” OR HICs). We conducted a search spanning January 2003 to March 2024, using five databases (Scopus, Embase, PubMed, EconLit, and Web of Science). January 2003 was chosen as the starting point to align with the early implementation period of major global health initiatives—specifically the President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria—which were initiated between 2002 and 2003. A higher level of global health activity and associated economic evaluations would be expected from this point onwards. Our search string remained consistent across databases to maintain search approach uniformity while allowing necessary adjustments for database-specific nuances. Recognising inherent differences in database characteristics, such as indexing practices and coverage, we conducted preliminary pilot searches to assess the performance of the initial strategy in each database. These revealed some variations—for instance, EconLit and Web of Science returned a high proportion of irrelevant results due to their broader indexing scopes, often capturing economic literature unrelated to health. In response, we refined the search string by limiting certain broad terms (e.g. economic, sepsis, neonatal, maternal) to title and abstract fields to improve precision. We also made minor syntax adjustments—such as adapting proximity operators or truncation symbols—to align with the requirements of each database and ensure consistent retrieval of relevant studies. Our cross-database modifications were driven by a commitment to maintaining relevance to the review’s focus while managing workload and resource allocation feasibility. However, we are confident that the fact that we also conducted an additional 90 searches, per database (i.e., a discrete search, which included the main search string, but modified “low and middle income countries” or “developing countries” to instead state each individual LMIC, per World Bank classification [32], captured all relevant sources of data on this topic. While our search was intentionally scoped to focus on key economic terms relevant to the review, with the aim of capturing studies most directly aligned with the review’s focus while maintaining feasibility, as a supplemental step to our comprehensive literature search, we conducted an additional search using Google Scholar between 29th-30th March 2024. We screened titles and, where necessary, abstracts, focusing on the first three pages (10 results per page) of a general search using the term “Neonatal Sepsis Costs.” One eligible study was identified on the first page, with no further relevant LMIC-focused studies found on subsequent pages. Given the geographic trends observed in our primary database search, we also conducted targeted searches for studies in Africa (2 pages) and India (4 pages), which yielded one additional study meeting our inclusion criteria. In total, the Google Scholar search contributed two additional studies to the final dataset. Of the two additional studies identified via Google Scholar, one appeared in the reference lists of five of the studies we assessed for eligibility and was ultimately included in four of the final included studies. The other had not been cited in any of the included references, highlighting the potential for relevant literature to be overlooked through both database searching and reference list screening. Reference lists of the screened publications were reviewed in a targeted, non-systematic manner to identify any additional studies, rather than as a formal snowballing procedure. Nonetheless, these results support the value of our focused Google Scholar search in enhancing the comprehensiveness of the review without compromising the precision and feasibility of the primary search strategy. Screening process Studies focused on impact; evaluation; intervention; comparison; utilisation; effectiveness; programme; and management were all included at title screening stage. Articles addressing issues related to healthcare management and health system/service implementation, while not central to the review’s focus, were deemed potentially relevant due to their potential inclusion of information pertaining to the cost of implementation. Abstracts were then reviewed at which point studies were excluded based on the following criteria: Information relating to Sepsis could not be meaningfully isolated from more general health data; Information relating to Sepsis could not be meaningfully isolated from more general health data; Review articles with no empirical data capture, Review articles with no empirical data capture, Non peer-reviewed articles including reports; books; or poster/dissertations where there was no subsequent published manuscript available; Non peer-reviewed articles including reports; books; or poster/dissertations where there was no subsequent published manuscript available; Studies that had not undertaken economic evaluation, or cost analysis to a reasonable degree (i.e., studies that did not clearly articulate any economic/cost-related focus); Studies that had not undertaken economic evaluation, or cost analysis to a reasonable degree (i.e., studies that did not clearly articulate any economic/cost-related focus); Studies that did not pass a quality rating (see CHEERS below). Studies that did not pass a quality rating (see CHEERS below). No additional limits (e.g. publication type, study design) were imposed and no other exclusion criteria were applied. The lead author screened all abstracts while the second author independently screened a subset (10%) of the articles. There was 87% inter-rater reliability, and differences were discussed and agreed. We used a rating scale to assess the completeness and quality of reporting in economic evaluations of health interventions. The rating scale was derived from the Consolidated Health Economic Evaluation Reporting Standards (CHEERS: 25) checklist (scores ranging from 5 to 25 across five domains), which served as a guide for identifying essential items for reporting in economic evaluations. Following this, all potential studies were rated based on the CHEERS guidelines. Creation of a rating approach: The rating approach condenses the comprehensive CHEERS guidelines into five key domains, reflecting essential aspects of economic evaluation quality. Title and Abstract: Evaluation of whether the title identifies the study as an economic evaluation and whether the abstract provides a structured summary including objectives, methods, results, and conclusions; Title and Abstract: Evaluation of whether the title identifies the study as an economic evaluation and whether the abstract provides a structured summary including objectives, methods, results, and conclusions; Introduction and Objectives: Assessment of the clarity of study objectives and the contextual background provided; Introduction and Objectives: Assessment of the clarity of study objectives and the contextual background provided; Methods: Review of the study’s perspective, comparators, time horizon, chosen health outcomes, and methods for measuring and valuing outcomes, as well as resource use and cost estimation; Methods: Review of the study’s perspective, comparators, time horizon, chosen health outcomes, and methods for measuring and valuing outcomes, as well as resource use and cost estimation; Results and Analysis: Examination of the clarity and comprehensiveness of the results presentation, including the discussion of uncertainty and variability, and the appropriateness of analytic methods; and. Results and Analysis: Examination of the clarity and comprehensiveness of the results presentation, including the discussion of uncertainty and variability, and the appropriateness of analytic methods; and. Discussion and Funding: Consideration of the discussion’s coverage of key findings, generalisability, limitations, and the disclosure of funding sources and potential conflicts of interest. Discussion and Funding: Consideration of the discussion’s coverage of key findings, generalisability, limitations, and the disclosure of funding sources and potential conflicts of interest. Scoring: Each domain was rated on a scale from 1 to 5 (i.e., 1 = Poorly reported or not reported; 2 = Insufficiently reported with major gaps; 3 = Partially reported with some limitations; 4 = Adequately reported with minor limitations; 5 = Well reported with comprehensive details). The scores for each domain are then summed to provide a total quality score for each study, with a maximum possible score of 25 (i.e., 21–25 = Excellent/Comprehensive and well-reported across all domains; 16–20 = Good/Adequately reported with minor limitations in some domains; 11–15 = Fair/Partially reported with some significant limitations; 6–10 = Insufficient/Insufficiently reported with major gaps in several domains; 1–5 = Poor/Poorly reported or not reported in most domains). Application of the rating scale: The lead author applied the rating scale to each included study, ensuring a consistent and streamlined assessment process. To ensure robustness of our findings, we excluded all studies rated as Poor (1–5) or Insufficient (6–10) from further analysis due to inadequate information on the cost evaluation. We removed one study which was purely the protocol for undertaking a systematic review of economic evaluations in this area but that did not provide data or execution of the proposed approach. Following all the steps outlined above, a final analysis set of 23 studies was identified. While CHEERS is primarily a reporting guideline, we applied its rating scale to assess reporting quality and to provide a structured, pragmatic evaluation of methodological rigor, recognizing that it does not constitute a formal risk-of-bias assessment. By excluding studies with poor or insufficient ratings (1–10), we mitigated the risk of incorporating studies with potential methodological flaws that could impact the reliability of our findings. Data Extraction Process: All data were extracted manually by the lead author. Consistent with the review’s stated aim of generating methodological and best practice insights, data extraction focused on aspects of study design and execution in economic evaluations of sepsis interventions in LMICs. Extracted elements included cost categories, data collection methods, cost calculation techniques, approaches to cost-effectiveness analysis, contextualisation of findings, and use of sensitivity analyses. Where available, recommendations for improving EE methods in LMICs were also recorded. Key elements were tabulated to provide a structured comparison across studies. These tables facilitated the identification of best practices and methodological insights, supporting the synthesis of findings. Results Database searches identified 527 citations, with 257 remaining after duplicate removal. An additional two studies were identified through systematic citations searches via Google Scholar as noted. Twenty-three papers met the criteria for inclusion in the review. Figure 1 outlines the screening process and the categories. PRISMA Flowchart Descriptives A total of 23 studies [33–55]—spanning research and data from over 40 countries—were included in the final analysis dataset (Appendix A). Of the 23 studies, 13 focused exclusively on countries in sub-Saharan Africa [33, 36, 37, 39, 42, 43, 45–47, 49, 51–53], and 9 focused on South Asian contexts (India, Pakistan, Bangladesh, and Nepal) [34, 35, 40, 41, 44, 48, 50, 54, 55]. One study [40] included data from both sub-Saharan Africa and South Asia. Sixteen of the 23 studies [34–39, 41, 43, 46–49, 51–53] were CEAs, with the remaining seven comprising five cost analysis studies (CAS) [33, 40, 44, 50, 54] and two cost-utility analyses (CUA) [45, 55]. While CAS identifies and categorises all costs associated with an activity or intervention, CEA and CUA extend this by comparing costs with health outcomes to assess intervention efficiency, with CUA further incorporating quality-of-life measures such as Quality-Adjusted Life Years (QALYs). The quality of economic evaluation was rated “good” or “excellent” in 19 of the 23 studies [33, 36–39, 41–43, 45–53, 55], based on the CHEERS checklist, meaning all sections (Title/Abstract, Introduction/Objectives, Methods, Results, and Discussion/Funding) were comprehensively reported. The studies, spanning 2003 to 2024, also show a clear upward trend in economic evaluations over time. Only one study was published between 2003 and 2009 [36], while 19 of the 23 studies [33, 35–48, 51, 52, 54, 55] were conducted between 2014 and 2024, reflecting the increasing focus on economic evaluations in LMIC healthcare in the past decade. Neonatal sepsis: Primarily sepsis vs. Mixed sepsis (bundled) While the initial focus of this review was to identify economic evaluations specifically targeting neonatal sepsis, only five of the 23 studies identified could be classified as evaluating cost-effectiveness for sepsis alone or as the primary focus [39, 51, 52, 54, 55]. The remaining 18 studies included sepsis as one component within broader evaluations of maternal and neonatal healthcare. However, given the ubiquity of sepsis in these settings—as a common and serious complication of childbirth and neonatal care—many of these bundled interventions addressed its prevention, diagnosis, or treatment alongside other conditions. For example, Jayanna et al. [40] assessed a nurse-led on-site mentoring programme to improve the quality of institutional births across primary health centres in two high-priority districts in South India. While the intervention targeted overall improvements in provider preparedness and facility readiness, it specifically measured improvements in management of maternal and neonatal sepsis, among other complications. Although not focused solely on sepsis, the study illustrates how bundled care improvement strategies can meaningfully affect sepsis-related outcomes, supporting the inclusion of such studies in this review. These 18 mixed-sepsis studies, though not exclusively focused on sepsis, were included because of their relevance to the economic evaluation of interventions that significantly impact sepsis outcomes. Studies like Jayanna et al. [40] exemplify how broader quality improvement initiatives in maternal and neonatal care inherently address sepsis and its economic implications. Key elements: Data extraction focused on capturing data relating to optimising the conduct of economic evaluations (EEs) in LMICs. The key elements that were identified therefore relate to study design and execution rather than individual study outcomes. These elements included: (1) Cost categories; (2) Methods of data collection; (3) Cost calculation methods; (4) Cost-effectiveness analysis techniques; (5) Contextualisation of findings; and (6) Sensitivity analyses. Additionally, recommendations for conducting EEs in LMICs within the reviewed studies were synthesised and are included in the Discussion section. Cost categories Cost data were predominantly categorised into seven key categories, and these are summarised in Table 1. Table 1Key cost categoriesCategory NameDescription# (%) of Studies IncorporatedDirect Medical CostsGeneral, routine healthcare expenses incurred as part of standard care, regardless of any specific intervention being evaluated such as hospitalisation costs, medication, diagnostic tests, and medical procedures.19 (82.6%)Programme CostsExpenses associated with implementing healthcare programmes, including personnel salaries, training, infrastructure, and ongoing operational costs.18 (78.3%)Capital CostsInvestments in infrastructure, equipment, and initial setup costs, often amortised over the equipment’s useful life.17 (79.3%)Indirect CostsBroader economic impacts such as productivity losses due to caregivers missing work, and long-term economic implications like DALYs.16 (69.6%)Specific Intervention CostsAdditional or targeted costs directly attributable to a particular intervention under study, above and beyond standard care. Examples: implementation of kangaroo mother care programs; neonatal resuscitation kits; training staff for a specific treatment protocol.15 (65.2%)Long term Management Costs and Healthcare ExpendituresCosts associated with ongoing patient management, including intervention-specific costs and standard-of-care medical expenditures.14 (60.9%)Economic Costs from Societal PerspectiveProgramme costs, health system costs, and user costs, over extended time horizons (e.g., 10 years), including broader societal impacts such as antimicrobial resistance*13 (56.5%)Note. Cost categories are presented as reported in original studies. Direct Medical Costs refer to general medical expenses such as hospitalization, medications, diagnostics, and standard medical procedures, while Specific Intervention Costs refer to costs directly associated with the intervention under study (e.g., staff training, program-specific equipment, or targeted treatments). These categories do not imply a strict hierarchical or subset relationship due to heterogeneity in reporting across studies; *Costs such as establishing laboratory capacity, conducting pathogen profiling, implementing antibiotic stewardship, and related provider training may be captured under Direct Medical Costs, Patient-Level Costs, Capital Costs, Programme Costs, or Specific Intervention Costs depending on the study. Their broader societal implications, including contributions to antimicrobial resistance, should be considered within the Societal Perspective (as reflected in the Societal Perspective line item) Key cost categories Note. Cost categories are presented as reported in original studies. Direct Medical Costs refer to general medical expenses such as hospitalization, medications, diagnostics, and standard medical procedures, while Specific Intervention Costs refer to costs directly associated with the intervention under study (e.g., staff training, program-specific equipment, or targeted treatments). These categories do not imply a strict hierarchical or subset relationship due to heterogeneity in reporting across studies; *Costs such as establishing laboratory capacity, conducting pathogen profiling, implementing antibiotic stewardship, and related provider training may be captured under Direct Medical Costs, Patient-Level Costs, Capital Costs, Programme Costs, or Specific Intervention Costs depending on the study. Their broader societal implications, including contributions to antimicrobial resistance, should be considered within the Societal Perspective (as reflected in the Societal Perspective line item) Less common cost categories were also identified, including direct non-medical costs such as transportation to healthcare facilities, accommodation, special diets, and nutritional supplements. In the context of neonatal sepsis, such societal costs are not only financial burdens but can act as decisive barriers to care-seeking, particularly when newborns require referral to higher-level facilities or present with sepsis after discharge. Capturing these costs is therefore essential for understanding both the household and broader societal impact of interventions. Support and administrative costs including overheads, administrative expenses, and logistical support necessary for programme management and implementation; and detailed breakdowns which provided meticulous breakdowns of costs into recurring (e.g., ongoing salaries, consumables) and one-time costs (e.g., initial training, capital expenditures). Methods of data collection Nineteen of the 23 studies employed quantitative methods and 12 used qualitative methods; eight of these studies used both approaches within a mixed methods design. In addition, four studies incorporated participant observation, and one study conducted a literature synthesis or meta-analysis. Table 2 presents a breakdown of the main methods and sources used for data collection. Table 2Data collection methods and sourcesMethodDescription# (%) of Studies IncorporatedSurveying and follow-up visitsSurveys were employed across various studies to gather data on events, outcomes, and participant responses, ensuring comprehensive longitudinal data collection.10 (43%)InterviewsInterviews with healthcare providers, caregivers, and key stakeholders provided qualitative insights and quantitative data on practices and perceptions related to maternal and neonatal health.9 (39%)Medical Records AnalysisAnalysis of medical records provided detailed quantitative data on patient demographics, treatments, and healthcare utilisation patterns.5 (22%)Costing ReviewsRetrospective costing reviews and financial record analysis were conducted to assess programme costs, economic impacts, and resource utilisation.4 (17%)Expert ConsultationSpecialists or professionals in the field were consulted to validate findings, provide insights, or refine methodologies, and critically, verify and contextualise the cost/economic models/model inputs.4 (17%)Structured Data Collection ToolsStructured tools facilitated comprehensive data collection on costs, resource utilisation, and economic indicators.3 (13%)Time-motion StudiesTime-motion studies quantified the time spent on healthcare activities by providers, offering insights into operational efficiencies and resource allocation.2 (9%)Decision-Analytic ModelsDecision-analytic models simulated intervention outcomes and economic evaluations, integrating expert opinions and literature reviews.2 (9%)Population ModellingPopulation-based modelling techniques estimated costs and effectiveness of interventions based on epidemiological and demographic data.2 (9%)Meta-AnalysisMeta-analytic techniques synthesised data from multiple sources and studies to provide pooled estimates and validate findings.1 (4%) Data collection methods and sources Cost calculation Across studies, a variety of cost calculation methodologies (see Table 3) were commonly employed demonstrating that adaptability to local contexts and transparency and reproducibility are both crucial to resource allocation and policy making in LMIC healthcare settings. Table 3Common cost calculation methodologiesApproachDescriptionStudies (Appendix A)Ingredients-based approachDetailed itemisation of inputs (e.g., personnel, equipment, medications) sourced from standardised databases or local prices. Enhances transparency and reproducibility in cost estimations.[38, 41, 47]Activity-based costing or micro-costingLinks costs directly to specific patient activities or hospital processes. Provides a granular view of direct and indirect costs per patient or service.Notably observed in [39]; occasionally in others [45, 50]Statistical measures (mean, median etc.)Summarise cost data, especially in cases of skewed distributions. Mean, median, and interquartile ranges provide insights into central tendencies and variability in cost estimates.[33, 50]Discounting and present value calculationAdjusts costs to present values using discount rates, enabling comparisons of costs and benefits over time from an economic perspective. For acute conditions like sepsis, discounting has minimal impact but is included because it appeared in the reviewed studies.[35, 36, 48, 53]Societal perspective and indirect costsConsiders broader economic impacts such as productivity losses, travel expenses, accommodation, and informal payments not covered by formal medical reimbursements. In the context of neonatal sepsis, these costs can present major barriers to care-seeking, particularly where referral to higher-level facilities or post-discharge treatment is required. Provides insights into healthcare system and household impacts.[39, 54, 55]Specialised tools and databasesUtilises tools like the Cost of Integrated Neonatal Care tool or databases such as WHO-CHOICE and NHSCD for standardised cost estimates, ensuring consistency across different contexts.[46, 49]While most studies aligned with the tabulated categories, some variations in methodology were noted (e.g., using the value of statistical life methodology to assign monetary values to dalys averted [53]). This reflects the diverse approaches taken to address specific research questions Common cost calculation methodologies While most studies aligned with the tabulated categories, some variations in methodology were noted (e.g., using the value of statistical life methodology to assign monetary values to dalys averted [53]). This reflects the diverse approaches taken to address specific research questions Cost-effectiveness analysis Health impacts were systematically assessed and integrated into the economic evaluations of healthcare interventions, encompassing the calculation of key metrics such as DALYs, QALYs, and other relevant health indicators across reviewed studies. DALYs and QALYs were prominently used to assess healthcare interventions in several studies. DALYs, employed in studies [34, 38, 45, 47], combine Years of Life Lost (YLL) due to premature mortality and Years Lived with Disability (YLD) using specific disability weights to measure disease burden. QALYs, featured in studies [45, 48, 54], adjust life years by a health-related quality factor, providing broader insights into health outcomes beyond mortality. Both metrics offer quantifiable measures to understand the health impacts of interventions. Incremental Cost-Effectiveness Ratios (ICERs), used in studies [37, 42, 47], compare the additional costs required for incremental health benefits between interventions, aiding economic decision-making. Other approaches included reporting direct reductions in mortality rates and various clinical outcomes like reductions in neonatal deaths, disease-specific improvements, and increased survival rates. These outcomes, while valuable, were not always translated into standardised metrics like DALYs or QALYs, showcasing a diverse range of methods to demonstrate cost-efficacy and health impact. Contextualisation Costs were contextualised in the reviewed studies in several different ways (see Table 4), ensuring comparability and relevance across different economic settings and timeframes. The methods used for currency conversion, inflation adjustment, and application of discount rates are highlighted, reflecting the diverse approaches taken to standardise cost data. Table 4Contextualisation methods used in studiesTopicDetailsStudies (Appendix A)Inflation adjustmentsAdjusting for inflation was a common practice to ensure costs were presented in current values, enhancing comparability over time. For example, costs were adjusted using the Gross Domestic Product deflator in Bangladesh [41] and the Consumer Price Index in the United States [36].[35, 36, 41, 42, 46, 53]Country-specific dataIncorporating country-specific data was crucial for accurate cost assessments. Studies tailored their analyses to reflect local epidemiology, demography, and healthcare costs.[42, 43, 46, 47, 54]Conversion to International Dollars and exchange ratesA number of studies converted costs into international dollars using purchasing power parity (PPP) conversion factors to account for differences in price levels across countries. Similarly, several studies used exchange rates to ensure comparability across countries and adjusted costs for inflation to maintain consistency with local consumer price indices.[33, 39, 50, 55]Local economic conditionsCosts contextualised to reflect local economic conditions in specific regions or countries, to ensure that cost assessments were grounded in regional economic realities. For example, in study [34], costs were scaled up to national estimates for India, while in Ethiopia [42], national analysts incorporated country-specific inputs to ensure realistic cost assessments.[34, 40, 42, 45, 47]Discount ratesApplication of discount rates to future costs/outcomes used to contextualise economic evaluations and ensure that present values accurately reflected the time preference for money, aligning with WHO guidelines for economic evaluations.[36, 48, 53]Economic context and health expenditureStudies often provided insights into broader economic context, highlighting resource scarcity and healthcare expenditure per capita. This approach helped contextualise costs within the realities of healthcare delivery in different settings.[42, 47, 49, 52]Specific programme or provider perspectiveCosts were assessed from the perspective of specific healthcare providers or programmes, focusing on detailed healthcare setting and practice considerations such as health centre costs and implementation costs of decision support systems.[37, 38, 40, 44]Societal perspectiveCosts were analysed from a societal perspective, considering programme costs, health system costs, and user costs over a specified time horizon. This includes both direct household expenses (e.g., transport, accommodation, lost wages) and broader economic effects, which are particularly important for conditions like neonatal sepsis where barriers to accessing timely treatment can shape outcomes. This approach provided insights into broader societal impacts of interventions.[41, 42] Contextualisation methods used in studies Lack of contextualisation was also an issue in some cases. Although many studies undertook this important step in economic evaluations, some failed to provide explicit details on cost contextualisation. For instance, one study [45] did not account for inflation or convert costs to international dollars, while another [55] reported costs in Indian Rupees without considering the international context. This lack of contextualisation may hinder the comparability and applicability of these findings across different economic settings. Sensitivity analyses Across the 23 studies, we can draw several initial insights regarding the methodologies and their applications in economic evaluations. Below is a synthesised overview of the types of sensitivity analyses conducted, and the discrete parameters tested (Tables 5 and 6, respectively). Table 5Types of sensitivity analyses conducted, and studies employing these methodsMethodDescriptionStudies (Appendix A)One-way Sensitivity Analysis (OSA)The most prevalent approach where one parameter at a time is varied while keeping others constant to assess its impact on the results[33, 37, 39, 41–43, 47, 48, 52, 53]Multi-way Sensitivity AnalysisExtends the OSA by varying multiple parameters simultaneously to understand the combined effect on the outcomes[39, 41, 43, 46, 49, 53]Probabilistic Sensitivity AnalysisUses distributions for key parameters and conducts numerous simulations (e.g., Monte Carlo simulations) to capture a range of possible outcomes and their probabilities[43, 47, 50, 53, 55]Deterministic Sensitivity AnalysisLike OSA, but specifically examines the impact of predetermined changes in parameters[37, 38, 48, 49, 53]Incremental Net Benefit AnalysisEvaluates cost-effectiveness for specific subgroups or scenarios, providing insights into variations in cost-effectiveness across different populations or conditions[36] Types of sensitivity analyses conducted, and studies employing these methods Table 6Parameters and variables tested in sensitivity analysesParameterDescriptionStudies (Appendix A)CostsIncluding personnel/staffing, fuel, equipment, and training costs. Sensitivity to these costs helps in understanding the economic viability under different cost structures[33, 35, 38, 39, 48, 49]Effectiveness estimatesVariations in the effectiveness of interventions are tested to gauge the robustness of cost-effectiveness results under different efficacy scenarios[42, 43, 46, 47, 49, 53]Demographic and epidemiological factorsIncluding disease incidence, mortality rates, and population coverage, providing insights into how changes in these factors influence economic outcomes[34, 42, 43, 46, 51]Discount ratesAdjusting the discount rates to see how future costs and benefits impact the present value calculations[37, 38, 43]Willingness-to-pay thresholdsAnalysing how changes in societal willingness-to-pay affect the perceived cost-effectiveness of interventions[36, 47] Parameters and variables tested in sensitivity analyses Sensitivity analyses confirmed the robustness of the economic evaluations in several studies, indicating that the interventions remained cost-effective under various plausible scenarios [33, 43, 46, 47, 53]. Labour costs, vaccination costs, and intervention effectiveness were identified as key drivers affecting overall cost-effectiveness in studies [35, 51, 55]. There was significant variability in how sensitivity analyses were conducted across different studies, reflecting different study designs, available data, and contexts, as shown in studies [39, 41, 43, 46, 49, 55]. Discussion This systematic review synthesised findings from 23 studies focusing on economic evaluations related to maternal and neonatal healthcare in LMICs. Most of the studies were CEAs (16 out of 23), highlighting a strong emphasis on assessing the economic efficiency of healthcare interventions. Importantly, 19 of these 23 studies (83%) were rated as “good” or “excellent” per CHEERS criteria, underscoring rigorous study design and comprehensive reporting [25]. This is considerably higher than the proportions reported in several recent systematic reviews examining the scope and quality of economic evaluations in European settings [56, 57]. By contrast, it is similar to findings from a recent review of economic evaluations in LMICs, in which 90% of studies reported all key elements of the CHEERS checklist [58]. However, our decision to exclude studies ranked as “Poor” or “Insufficient” by definition created a higher-quality set of studies. Although sepsis was a focal point in neonatal and maternal healthcare interventions, and had been an initial focus for the study, only a subset of studies specifically evaluated the cost-effectiveness of sepsis management on its own (5 out of 23). Most studies integrated sepsis management within broader maternal and neonatal healthcare packages, recognising sepsis as a significant complication in LMIC settings. This integrated approach reflects the prioritisation of maximising overall health outcomes by addressing sepsis alongside other healthcare priorities. Several key elements emerged as crucial in the design and conduct of high-quality economic evaluations in LMICs, demonstrating methodological diversity and robustness across the reviewed studies. The studies covered a wide range of cost categories essential for economic evaluations [5, 11], with direct medical costs (82.6%), programme costs (78.3%), and capital costs (73.9%) being the most frequently discussed. Quantitative methods predominated (82.6%) perhaps reflecting a perspective that rigorous evaluation requires quantitative data, though they were frequently combined with other methods. Follow-up visits, including assessment via surveys, were reported in 43% of studies, supporting longitudinal evaluation of outcomes in many cases. Cost calculation methodologies varied widely, though the ingredients-based approach was prominently utilised [5]. The inclusion of statistical measures, discounting, and societal perspectives highlighted the complexity of economic evaluations in these settings. These methodologies underscored the adaptability to local contexts and emphasised transparency and reproducibility in cost estimations, which are crucial for informing resource allocation and policy decisions in LMIC healthcare settings. The reviewed studies employed various metrics, such as DALYs, QALYs, and ICERs, to assess the economic impact of healthcare interventions. These metrics provide valuable insights into both the economic efficiency and health benefits of interventions across diverse LMIC contexts [5, 59, 60]. Additionally, costs were contextualised using methods such as Purchasing Power Parity (PPP), inflation adjustments, and discount rates to enhance comparability across different economic settings and timeframes. However, gaps in contextualisation were evident as a notable number of studies did not adequately account for inflation or failed to convert costs into international dollars. This oversight could compromise the comparability of findings across different economic settings. Such lack of contextualisation not only limits the reliability of economic assessments but also hinders the applicability of research outcomes in guiding evidence-based decision-making. Sensitivity analyses were conducted in the majority of studies (78.3%), demonstrating the robustness of economic evaluations by assessing the impact of parameter uncertainties on study outcomes [59, 60]. One-way sensitivity analysis (43.5%) and probabilistic sensitivity analysis (34.8%) were the most prevalent approaches. Commonly altered parameters included intervention costs, treatment efficacy, discount rates, and healthcare utilisation rates. By varying these parameters, studies assessed how changes could affect the cost-effectiveness outcomes, thereby enhancing the reliability and generalisability of the results. However, five of the 23 studies did not report conducting any sensitivity analysis [34, 40, 44, 45, 54]. This absence is particularly problematic as sensitivity analysis is a critical component of economic evaluation [30]. Without it, the reliability and generalisability of the findings are questionable, potentially undermining confidence in the cost-effectiveness conclusions and making it challenging for policymakers to make informed decisions. Nine of the 23 reviewed studies provided diverse recommendations aimed at improving the economic evaluation of healthcare interventions across different contexts advocating for such elements as: expanding the scope of economic evaluations to include larger sample sizes and additional healthcare facilities to enhance the generalisability of findings; generating policy-relevant evidence; developing and utilising tools, such as calculators, to estimate cost-effectiveness across varied contexts and facilitate evidence-based decision-making; as well as, more broadly, calling for more, and rigorous CEA studies to be undertaken [33, 38, 39, 42, 47, 49–52]. However, while these studies often demonstrate the economic impact of interventions, they frequently omit practical, actionable guidance necessary for rigorous evaluations and data quality improvements. This aligns with recent research, which highlights that only a small percentage of low-income and lower-middle-income countries have developed official guidelines for economic evaluations. Even in the few instances where guidelines exist, significant methodological gaps remain, exacerbating challenges in standardising approaches and implementing high-quality evaluations in LMICs [7, 61]. Moreover, most individual EE studies fail to provide explicit recommendations or practical insights from their own experiences conducting EEs in resource-constrained settings (e.g., what worked well and what didn’t), which could serve as a guide for subsequent research groups. This further complicates the development of optimised approaches tailored to these settings. The lack of both official and researcher-provided methodological guidance for policymakers and researchers perpetuates challenges in improving data quality and the rigor of evaluations, underscoring the need for a standardised, adaptable framework to enhance the utility of economic evaluations in LMIC healthcare settings. Recommendations for optimising economic evaluations of neonatal sepsis in LMICs To address these gaps, we present a succinct, actionable guide for designing and conducting robust economic evaluations in neonatal sepsis. Grounded in insights from high-quality studies, this list consolidates key elements that are often underemphasised yet critical for achieving methodological rigour and real-world applicability. Rigorous Data Collection Methods: Employ longitudinal surveys, follow-up visits, and health facility data reviews to gather detailed and reliable data on costs and health outcomes. Supplement these with interviews and focus groups with healthcare providers and patients to provide contextual insights. Rigorous Data Collection Methods: Employ longitudinal surveys, follow-up visits, and health facility data reviews to gather detailed and reliable data on costs and health outcomes. Supplement these with interviews and focus groups with healthcare providers and patients to provide contextual insights. Comprehensive Cost Assessment: Include direct medical costs (e.g., medications, hospital stays), programme costs (e.g., training, outreach), capital costs (e.g., infrastructure), and indirect costs (e.g., lost productivity). Utilise hospital records, national databases, and surveys to capture all relevant cost components. Furthermore, whenever possible, incorporate broader societal costs, such as caregiver burden, transportation costs, and costs borne by other sectors of society (e.g., productivity losses from employers or other affected industries), as these can substantially increase disease burden estimates [62] and can influence the overall economic evaluation and policy decisions in LMIC contexts [61]. Comprehensive Cost Assessment: Include direct medical costs (e.g., medications, hospital stays), programme costs (e.g., training, outreach), capital costs (e.g., infrastructure), and indirect costs (e.g., lost productivity). Utilise hospital records, national databases, and surveys to capture all relevant cost components. Furthermore, whenever possible, incorporate broader societal costs, such as caregiver burden, transportation costs, and costs borne by other sectors of society (e.g., productivity losses from employers or other affected industries), as these can substantially increase disease burden estimates [62] and can influence the overall economic evaluation and policy decisions in LMIC contexts [61]. Integration of Health Outcomes and Economic Metrics: Track key health outcomes (e.g., mortality, morbidity, quality of life) over appropriate time horizons to capture long-term effects. Utilise DALYs and QALYs to measure health benefits and ICERs to assess cost-effectiveness. Integration of Health Outcomes and Economic Metrics: Track key health outcomes (e.g., mortality, morbidity, quality of life) over appropriate time horizons to capture long-term effects. Utilise DALYs and QALYs to measure health benefits and ICERs to assess cost-effectiveness. Contextualisation of Costs: Apply economic adjustments such as PPP, inflation adjustments, and discount rates to ensure comparability across different settings and timeframes. Critically, there is a need to customise the evaluation framework to reflect local healthcare delivery models, resource availability, and economic conditions. In the case of maternal and neonatal sepsis, contextualisation is particularly important given the condition’s unique sequelae and prevention pathways, for example, long-term disabilities such as hearing loss following neonatal meningitis, or maternal screening and prophylaxis for Group B Streptococcus to prevent neonatal sepsis. These illustrate how economic analyses must be tailored to the clinical realities of sepsis rather than applied generically across maternal and child health. Contextualisation of Costs: Apply economic adjustments such as PPP, inflation adjustments, and discount rates to ensure comparability across different settings and timeframes. Critically, there is a need to customise the evaluation framework to reflect local healthcare delivery models, resource availability, and economic conditions. In the case of maternal and neonatal sepsis, contextualisation is particularly important given the condition’s unique sequelae and prevention pathways, for example, long-term disabilities such as hearing loss following neonatal meningitis, or maternal screening and prophylaxis for Group B Streptococcus to prevent neonatal sepsis. These illustrate how economic analyses must be tailored to the clinical realities of sepsis rather than applied generically across maternal and child health. Transparent Cost Calculation: Use ingredients-based approaches to itemise all components of interventions for transparency. Employ activity-based costing to allocate costs based on specific healthcare activities, enhancing accuracy. Transparent Cost Calculation: Use ingredients-based approaches to itemise all components of interventions for transparency. Employ activity-based costing to allocate costs based on specific healthcare activities, enhancing accuracy. Sensitivity Analyses: Conduct one-way sensitivity analysis and probabilistic sensitivity analysis to explore parameter uncertainties, with the latter being the most comprehensive method of dealing with various forms of uncertainty in economic evaluation [63]. Focus on varying intervention costs, treatment efficacy, discount rates, and healthcare utilisation rates to assess their impact on cost-effectiveness outcomes. Sensitivity Analyses: Conduct one-way sensitivity analysis and probabilistic sensitivity analysis to explore parameter uncertainties, with the latter being the most comprehensive method of dealing with various forms of uncertainty in economic evaluation [63]. Focus on varying intervention costs, treatment efficacy, discount rates, and healthcare utilisation rates to assess their impact on cost-effectiveness outcomes. Reflection and Insights: Study authors should include reflections on challenges encountered and successful strategies employed during data collection and analysis. Sharing these insights can provide practical guidance for future researchers facing similar challenges to the implementation and execution of economic evaluations in LMIC settings. Reflection and Insights: Study authors should include reflections on challenges encountered and successful strategies employed during data collection and analysis. Sharing these insights can provide practical guidance for future researchers facing similar challenges to the implementation and execution of economic evaluations in LMIC settings. Policy and Practice Implications: Study authors should provide clear, evidence-based recommendations for policymakers and healthcare practitioners to optimise resource allocation and improve sepsis management strategies. Involve local stakeholders in the design and implementation of the evaluation to ensure relevance and applicability. Policy and Practice Implications: Study authors should provide clear, evidence-based recommendations for policymakers and healthcare practitioners to optimise resource allocation and improve sepsis management strategies. Involve local stakeholders in the design and implementation of the evaluation to ensure relevance and applicability. Our recommendations, drawn from the data extracted in our review, largely align with established principles set out in existing guidance, including the CHEERS reporting standards [25] and widely used guidelines for reviewing economic evaluations developed by Drummond et al. [64] and are tailored to address persistent methodological gaps and practical challenges in LMIC contexts, with particular relevance to evaluations of maternal and neonatal sepsis interventions. These prior frameworks provide valuable tools for assessing and reporting the quality of economic evaluations, with strong emphasis on transparency in costing and methodological rigor. While they highlight the importance of considering contextual variability, this is primarily framed from an economic or resource-costing perspective, rather than in terms of implementation realities encountered during the conduct of a study. In contrast, our Recommendations 7 and 8 specifically call for individual studies to share practical, study-derived insights — for example, unanticipated barriers, deviations from planned methodology, or context-specific workarounds — to support subsequent research efforts and facilitate more realistic, context-sensitive policymaking. As demonstrated in studies like the Smart Triage evaluation in Eastern Uganda [22], challenges in ethical review processes, staff engagement, and the need for adaptive implementation strategies have been explicitly described — the kind of granular detail that is critical for future research design in similarly resource-constrained environments. It is therefore also important to acknowledge that while these recommendations represent an ideal approach, practical research in LMICs often faces significant resource constraints and logistical challenges. Thus, not every study will be able to implement all elements due to limitations in funding, data availability, or infrastructure. For instance, although ingredients-based costing is recommended—because, as other studies note (e.g., 7), it enables more detailed analysis of variation in costs and cost-effectiveness—a gross costing or top-down method may be more feasible in certain contexts. These approaches rely on non-patient-specific reference costs (e.g., diagnosis-related groups from national administrative databases). Interestingly, one comparison found that ingredients-based methods were more commonly used in LMICs than in high-income countries (68% vs. 10%), suggesting some adaptability and existing momentum in LMIC contexts [7]. Nonetheless, prioritising these ideal methodological elements wherever possible can substantially improve the rigour, reliability, and policy relevance of economic evaluations. Even incremental improvements can help strengthen the evidence base and support the development of more effective, context-sensitive healthcare interventions. Limitations This systematic review has some limitations. While the CHEERS checklist ensured a standardised assessment of methodological quality, variability in reporting practices across studies may still have influenced our synthesis. Further, while we focused on identifying and including primarily higher-quality studies, similar to Garg [65], we used a modified version of the Consolidated Health Economic Evaluation Reporting Standards checklist to appraise the studies (Five core CHEERS domains, each scored 1–5, versus the comprehensive 24-item list). Nonetheless, the fact that we excluded studies rated as providing poor or insufficient data on their economic approach suggests our included studies are of strong quality. Abstract screening and study inclusion were predominantly conducted by a single reviewer. This approach was transparently reported and supplemented by a subset check with a second reviewer, but it is possible that it may have introduced some risk of selection or extraction bias compared with the use of two independent reviewers. Another limitation is that publication bias remains a concern, as studies with negative or inconclusive findings may be underrepresented, and additionally, despite our comprehensive per-country search, some relevant studies may have been missed due to language restrictions or database limitations. The included studies evaluated diverse interventions, limiting direct comparisons, and methodological differences in cost analysis approaches further complicate synthesis. While this review highlights key gaps in the economic evaluation of sepsis care, further research with standardised methodologies and a greater focus on LMIC contexts is needed. Also, our review did not explicitly extract implementation-related information, as this was not commonly reported or clearly delineated in the methodological descriptions of the included studies. This lack of transparency may hinder assessments of real-world feasibility [57, 66], particularly in LMIC contexts, where such costs can significantly affect adoption and sustainability [67]. Finally, only a minority of included studies (5 of 23) focused exclusively on maternal or neonatal sepsis, with most evaluating broader maternal and neonatal care bundles in which sepsis was one of several outcomes. This limits the ability to draw conclusions that are entirely sepsis-specific, and readers should interpret the findings in the context of methodological insights rather than condition-specific cost-effectiveness results. Future research could incorporate additional sepsis-focused studies to develop a more targeted analytical framework. Conclusion The findings of this systematic review have important implications for policy, practice, and research in maternal and neonatal healthcare in LMICs, with relevance to sepsis management. While only a minority of included studies (5 of 23) focused exclusively on sepsis, the broader set of evaluations of maternal and neonatal care interventions provides valuable methodological insights that can be applied to sepsis-focused economic evaluations. From a policy perspective, evidence generated from cost-effectiveness analyses can inform resource allocation decisions, guide priority-setting exercises, and facilitate the development of evidence-based guidelines for sepsis management particularly in contexts where maternal and neonatal sepsis contributes substantially to morbidity and mortality [68]. By identifying cost-effective interventions and strategies, policymakers in LMICs can optimise the allocation of limited healthcare resources to maximise health outcomes and minimise economic burden [13, 69]. At the healthcare delivery level, methodological insights from the reviewed studies can support healthcare practitioners in designing, implementing, and evaluating interventions for sepsis within broader care bundles, optimising resource use and improving patient outcomes [70]. By understanding the cost-effectiveness of different interventions, healthcare providers can tailor treatment strategies to local contexts, optimise resource utilisation, and improve patient outcomes. Moreover, CEAs can support advocacy efforts to mobilise resources and garner political support for sepsis prevention and management initiatives [60]. Our systematic review of 23 studies on economic evaluations in maternal and neonatal healthcare across LMICs highlights methodological diversity, strengths in reporting, and areas for improvement, including gaps in sensitivity analyses and the need for clearer reporting of assumptions. These findings underscore the importance of standardised protocols, transparent reporting, and practical guidance to support future economic evaluations. Standardised protocols and practical reflections are essential to guide policymakers and researchers in improving healthcare outcomes and resource allocation strategies in LMIC settings. Even when sepsis is embedded within broader interventions, applying these methodological lessons can strengthen the design, comparability, and interpretability of economic evaluations in this critical area, ultimately supporting better-informed decisions in LMIC settings. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements Not applicable. Author contributions All authors contributed to the conception and design of the review, including development of the search strategy. Data extraction was carried out by the first two authors, with the first author taking primary responsibility. All authors contributed to the interpretation of findings, drafting, and critical revision of the manuscript, and approved the final version. Funding Funding for an overall programme of research looking at the economic issues pertaining to the implementation of diagnostic tools into LMICs is funded by the Irish-funding agency, Taighde Éireann (TÉ), however, TÉ had no role in this review. Data availability The full search strategy is provided in the body of the manuscript. No formal data extraction form/analytic code was used, as data were extracted manually with a focus on methodological domains rather than quantitative outcomes. No additional materials are publicly available. Declarations Ethics approval and consent to participate Not applicable. This study is a systematic review of published literature and did not involve human participants or primary data collection. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes We also ran analysis using the UK variant spelling (septicaemia) and results did not change. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The full search strategy is provided in the body of the manuscript. No formal data extraction form/analytic code was used, as data were extracted manually with a focus on methodological domains rather than quantitative outcomes. No additional materials are publicly available.